For people with certain BRCA mutations, activating the immune system could be a promising treatment

Treatments that use the immune system to fight cancer have greatly improved outcomes for some people with cancer. Scientists are learning more about why some people respond so much better than others to these drugs.

One major factor is something called tumor mutation burden (TMB) – the number of DNA changes a tumor has. Studies by researchers at Memorial Sloan Kettering and elsewhere have shown that tumors with high TMB tend to respond better to immune checkpoint inhibitors. In 2017, the U.S. Food and Drug Administration approved the checkpoint inhibitor pembrolizumab (Keytruda®) for the treatment of cancers with a type of genetic defect called mismatch repair deficiency (MMR).

MMR is one of several DNA repair pathways that cells use to correct errors in DNA. Mutations in this pathway lead to defective DNA repair and thus to higher TMB. Alongside MMR, the most commonly mutated DNA repair pathway is called homologous recombination, which repairs double-stranded breaks in DNA (in other words, when both sides of the DNA “ladder” are broken). The genes of cancer predisposition BRCA1 is BRCA2 belong to this path. When they are mutated, DNA damage builds up and increases the risk of developing several types of cancer, including breast, ovarian, prostate and pancreatic cancers.

MSK scientists are now reporting that mutations in one BRCA gene, but not the other, produce tumors that respond well to immunotherapy.

“When we started this work, we thought tumors with both types of homologous recombination deficiency would respond to immunotherapy based on the high mutation load,” says physician-scientist Nadeem Riaz. “But we found that instead BRCA2– mutated tumors responded much better than BRCA1 tumors. “

The unexpected results, which were published on November 16 in the journal Cancer Nature, it can have implications for the types of treatments people are subjected to BRCA2 mutations should be considered.

A surprising divergence

The researchers made their findings using both human data and mouse models. When they compared tumor mutations and clinical information from patients treated with immunotherapy at MSK, they found a direct correlation between the mutations BRCA2 and better survival after treatment.

To confirm that this correlation was more than just a chance discovery, they created genetically modified mouse models of BRCA1– is BRCA2– mutant breast and colorectal cancers. In both cases, they found that only the BRCA2– mutant tumors responded to treatment with checkpoint inhibitors.

As well as being surprising, the results were a bit counterintuitive.

“Five years ago, people probably would have thought BRCA1 it would have been the most immunogenic tumor, “says Dr. Riaz.” This is due to the two types, BRCA1-Mutant tumors tend to have more immune cells within them. It might be expected that having more immune cells means a better response to immunotherapy. But in fact, it was the file BRCA2– mutant tumors that showed the best response “.

Self BRCA1 is BRCA2 they are both involved in homologous recombination and both lead to a higher TMB, because it is only the BRCA2-mutants that appear to respond to immunotherapy?

According to the study authors, it may have to do with the type of mutations each produces. Mutant BRCA2produces smaller deletions in the DNA sequence, for example by removing a DNA base “letter”. These mutations shift the reading frame of genes and change the way the DNA sequence is translated into proteins. Imagine the gene is a phrase that says, “I like chocolate ice cream”. Deleting a DNA letter could change the sentence to “I like hocolatei cec ream”. The immune system detects these erroneous proteins as foreign and attacks the cells that contain them. In reverse, BRCA1 it creates several types of mutations, which are not so easily detectable by the immune system.

Jorge Reis-Filho, physician-scientist of the MSK Department of Pathology and collaborator of the Cancer Nature study, says the findings underscore the importance of testing hypotheses. “Sometimes we think we know biology and know what to expect, but when we investigate in detail using the right tools, the results surprise us,” he says.

“Often it’s not what we don’t know that gets us into trouble, it’s the things we think we know for sure that can lead us astray,” he adds.

Make treatments more precise

The new publication is the first to emerge from the Precision Radiation Oncology Initiative, led by Dr. Riaz. Created by the chairman of MSK’s oncology radiotherapy department, Simon Powell, the initiative aims to make radiation a type of targeted therapy when used in conjunction with other treatments such as immunotherapy. Since radiation damages DNA and forces cells to use their DNA repair pathways to repair the damage, the DNA repair defects that cancer cells often have can be exploited against them.

Although these new findings need to be confirmed by others and validated in clinical trials, they suggest that people with BRCA2-Mutant tumors may be considered enrolling in immunotherapy clinical trials. Several studies are currently enrolling people with BRCA-mutant tumors.

###

This study was funded in part through the National Institutes of Health (Cancer Center Support Grant P30 CA008748, R01 CA205426, R35 CA232097 and U54OD020355), Pershing Square Sohn Foundation, PaineWebber, Stand Up 2 Cancer, STARR Cancer Consortium, AACR Translational Immunology, Early Independence Award from the Director of the NIH (DP5-OD028171), Burroughs Wellcome Fund, Precision Immunotherapy Kidney Cancer Fund and Frederick Adler Fund. MSK has licensed the use of TMB for the identification of patients benefiting from immune checkpoint therapy at PGDx. Dr. Reis-Filho reports Goldman Sachs’ personal / consulting expenses and membership in the advisory committees of VolitionRx, Page.AI, Invicro, Roche, Genentech, and Ventana, outside of the submitted work. Dr. Riaz has received research funding from BMS, Pfizer and REPARE Therapeutics and has been an ad hoc consultant for Illumina, REPARE Therapeutics and Mirati Therapeutics.

About Memorial Sloan Kettering (MSK):

As the world’s oldest and largest private cancer center, Memorial Sloan Kettering has dedicated more than 135 years to exceptional patient care, influential educational programs, and innovative research to discover more effective strategies to prevent, control and ultimately analysis, cure cancer. MSK is home to over 20,000 doctors, scientists, nurses and staff united by an unremitting dedication to defeating cancer. Today we are one of 51 National Cancer Institute-designated Comprehensive Cancer Centers, with cutting-edge science and technology that support innovative clinical trials, personalized treatments and compassionate care for our patients. We also train the next generation of clinical and scientific leaders in oncology through our ever-evolving educational programs, here and around the world. Year after year, we are ranked among the top two cancer hospitals in the country, consistently recognized for our expertise in adult and pediatric oncology specialties. http: // www.mskcc.org.